Kentaro Sudo

1.4k total citations
55 papers, 921 citations indexed

About

Kentaro Sudo is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kentaro Sudo has authored 55 papers receiving a total of 921 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 20 papers in Surgery and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kentaro Sudo's work include Pancreatic and Hepatic Oncology Research (33 papers), Neuroendocrine Tumor Research Advances (15 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers). Kentaro Sudo is often cited by papers focused on Pancreatic and Hepatic Oncology Research (33 papers), Neuroendocrine Tumor Research Advances (15 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (13 papers). Kentaro Sudo collaborates with scholars based in Japan, United States and Germany. Kentaro Sudo's co-authors include Taketo Yamaguchi, Kazuyoshi Nakamura, Hiromitsu Saisho, Tomoaki Ishihara, Hiroyuki Kato, Taro Hara, Takeshi Ishihara, Tadamichi Denda, Junji Furuse and Tomohiro Yamaguchi and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and Scientific Reports.

In The Last Decade

Kentaro Sudo

51 papers receiving 894 citations

Peers

Kentaro Sudo
Panagiotis Skordilis Greece
Kazuhiko Nakagami Japan
Wai‐Key Yuen Hong Kong
Ki Jung Yun South Korea
Morten Hagness Norway
Ahmad Mokatrin United States
Jun Chul Chung South Korea
Yoshimasa Shiraishi Japan
Akiyuki Kanzaki Japan
Dilip Parekh United States
Panagiotis Skordilis Greece
Kentaro Sudo
Citations per year, relative to Kentaro Sudo Kentaro Sudo (= 1×) peers Panagiotis Skordilis

Countries citing papers authored by Kentaro Sudo

Since Specialization
Citations

This map shows the geographic impact of Kentaro Sudo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kentaro Sudo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kentaro Sudo more than expected).

Fields of papers citing papers by Kentaro Sudo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kentaro Sudo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kentaro Sudo. The network helps show where Kentaro Sudo may publish in the future.

Co-authorship network of co-authors of Kentaro Sudo

This figure shows the co-authorship network connecting the top 25 collaborators of Kentaro Sudo. A scholar is included among the top collaborators of Kentaro Sudo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kentaro Sudo. Kentaro Sudo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nakamura, Yoshiaki, Bennett Adam Caughey, Binbin Zheng-Lin, et al.. (2025). Clinicomolecular Profile and Efficacy of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapy for HER2 -Amplified Advanced Biliary Tract Cancer. JCO Precision Oncology. 9(9). e2400718–e2400718. 1 indexed citations
2.
Shibuki, Taro, Yoshiaki Nakamura, Makoto Ueno, et al.. (2024). Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.. Journal of Clinical Oncology. 42(3_suppl). 538–538.
3.
Todaka, Akiko, Mitsuhito Sasaki, Hideki Ueno, et al.. (2023). FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia — Nationwide Study Analysis. Anticancer Research. 43(9). 4115–4123. 1 indexed citations
4.
Sakai, Shunsuke, Takao Fujisawa, Kentaro Sawada, et al.. (2023). Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN.. Journal of Clinical Oncology. 41(4_suppl). 733–733.
5.
Sato, Junichiro, T. Shimizu, Yasuhiro Fujiwara, et al.. (2020). 17O A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors. Annals of Oncology. 31. S5–S6. 1 indexed citations
6.
Kobayashi, Noritoshi, Katsuhiro Omae, Yosuke Horita, et al.. (2020). FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Pancreatology. 20(7). 1519–1525. 6 indexed citations
7.
Todaka, Akiko, Nobumasa Mizuno, Masato Ozaka, et al.. (2018). Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Pancreas. 47(5). 631–636. 13 indexed citations
8.
Sasaki, Mitsuhito, Hironori Ueno, Katsuhiro Omae, et al.. (2017). Risk factors for febrile neutropenia (FN) in unresectable/recurrent pancreatic cancer(PC) patients(pts) receiving FOLFIRINOX (FFX) from JASPAC06 study. Annals of Oncology. 28. v260–v260. 2 indexed citations
9.
Ueno, Makoto, Hideyuki Takahashi, Kentaro Sudo, et al.. (2017). The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer. Annals of Oncology. 28. v41–v42. 3 indexed citations
10.
Sudo, Kentaro, et al.. (2017). Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 80(1). 195–202. 13 indexed citations
11.
Arai, Hiroyuki, Shuichi Hironaka, Takuto Suzuki, et al.. (2015). A retrospective study of early toxicity of weekly paclitaxel as second line chemotherapy for advanced gastric cancer. Annals of Oncology. 26. vii132–vii132. 1 indexed citations
12.
Nakamura, Kazuyoshi, Kentaro Sudo, Taro Hara, et al.. (2014). Signet Ring Cell Carcinoma of the Extrahepatic Bile Duct Diagnosed by Preoperative Biopsy: A Case Report. Case Reports in Gastroenterology. 8(3). 353–357. 7 indexed citations
13.
Sudo, Kentaro. (2014). S-1 in the treatment of pancreatic cancer. World Journal of Gastroenterology. 20(41). 15110–15110. 41 indexed citations
14.
Sudo, Kentaro, Takeshi Ishihara, Nobuto Hirata, et al.. (2013). Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology. 73(2). 389–396. 40 indexed citations
15.
Sudo, Kentaro, Taketo Yamaguchi, Takeshi Ishihara, et al.. (2010). Phase II Study of Oral S-1 and Concurrent Radiotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics. 80(1). 119–125. 56 indexed citations
16.
Tawada, Katsunobu, Taketo Yamaguchi, Takeshi Ishihara, et al.. (2009). Changes in tumor vascularity depicted by contrast-enhanced ultrasonography as a predictor of chemotherapeutic effect in patients with unresectable pancreatic cancer. Suizo. 24(4). 553–555. 2 indexed citations
17.
18.
Tawada, Katsunobu, Taketo Yamaguchi, Takeshi Ishihara, et al.. (2008). Changes in Tumor Vascularity Depicted by Contrast-Enhanced Ultrasonography as a Predictor of Chemotherapeutic Effect in Patients With Unresectable Pancreatic Cancer. Pancreas. 38(1). 30–35. 26 indexed citations
19.
Saiki, I, Kentaro Sudo, Kiyohiro Ikeda, & Tetsuo IWAKUMA. (2006). AN IMPROVEMENT OF THE STIFFNESS MODIFICATION METHOD TO FIND BIFURCATED PATHS AT A MULTIPLE BIFURCATION POINT. Doboku Gakkai Ronbunshuu A. 62(4). 782–793.
20.
Nakamura, Kazuyoshi, Taketo Yamaguchi, Tomoaki Ishihara, et al.. (2005). Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. British Journal of Cancer. 92(12). 2134–2139. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Panagiotis Skordilis Breakdown of academic impact, for papers by Kazuhiko Nakagami Breakdown of academic impact, for papers by Wai‐Key Yuen Breakdown of academic impact, for papers by Ki Jung Yun Breakdown of academic impact, for papers by Morten Hagness Breakdown of academic impact, for papers by Ahmad Mokatrin Breakdown of academic impact, for papers by Jun Chul Chung Breakdown of academic impact, for papers by Yoshimasa Shiraishi Breakdown of academic impact, for papers by Akiyuki Kanzaki Breakdown of academic impact, for papers by Dilip Parekh
Rankless by CCL
2026